VERSED Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Versed, and when can generic versions of Versed launch?
Versed is a drug marketed by HLR and Roche and is included in two NDAs.
The generic ingredient in VERSED is midazolam hydrochloride. There are nine drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the midazolam hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Versed
A generic version of VERSED was approved as midazolam hydrochloride by FRESENIUS KABI USA on June 20th, 2000.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VERSED?
- What are the global sales for VERSED?
- What is Average Wholesale Price for VERSED?
Summary for VERSED
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 47 |
| Clinical Trials: | 108 |
| Patent Applications: | 4,247 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | VERSED at DailyMed |
Recent Clinical Trials for VERSED
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Stanford University | Phase 2 |
| Lawson Health Research Institute | Phase 3 |
| National Institute of Mental Health (NIMH) | Phase 3 |
US Patents and Regulatory Information for VERSED
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hlr | VERSED | midazolam hydrochloride | INJECTABLE;INJECTION | 018654-002 | May 26, 1987 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Hlr | VERSED | midazolam hydrochloride | INJECTABLE;INJECTION | 018654-001 | Dec 20, 1985 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Roche | VERSED | midazolam hydrochloride | SYRUP;ORAL | 020942-001 | Oct 15, 1998 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VERSED
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Hlr | VERSED | midazolam hydrochloride | INJECTABLE;INJECTION | 018654-002 | May 26, 1987 | ⤷ Sign Up | ⤷ Sign Up |
| Roche | VERSED | midazolam hydrochloride | SYRUP;ORAL | 020942-001 | Oct 15, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| Hlr | VERSED | midazolam hydrochloride | INJECTABLE;INJECTION | 018654-001 | Dec 20, 1985 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VERSED
See the table below for patents covering VERSED around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Hong Kong | 63481 | DIAZEPINE DERIVATIVES | ⤷ Sign Up |
| Argentina | 218433 | PROCEDIMIENTO PARA LA PREPARACION DE COMPUESTOS IMIDAZO(1,5-A)(1,4)DIACEPINICOS | ⤷ Sign Up |
| Norway | 149136 | ⤷ Sign Up | |
| Switzerland | 619953 | Process for the preparation of diazepine derivatives | ⤷ Sign Up |
| Spain | 462844 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
